OptimizeRx price target raised to $27 from $22 at Roth Capital

Roth Capital raised the firm’s price target on OptimizeRx (OPRX) to $27 from $22 and keeps a Buy rating on the shares after its “very strong” Q2 results. The firm cites the company’s revenues and adjusted EBITDA both sharply above forecasts. OptimizeRx is well positioned for accelerated growth in 2025 and beyond, an outlook that is still at odds with its still-muted 2025 revenue growth guidance of 13%-17%, the analyst tells investors in a research note.